R-ISS
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- R-ISS III≥ 3
- R-ISS II≥ 2
- R-ISS I≥ 1
The R-ISS calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include iss stage. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Revised International Staging System for multiple myeloma.
Clinical Indication
The R-ISS is indicated for bedside clinical practice to support Revised International Staging System for multiple myeloma.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
R-ISS I: ISS I + normal LDH + standard CA; R-ISS III: ISS III + (high LDH or high-risk CA); else R-ISS II.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| iss_stage | int | Yes | ISS I/II/III (albumin + beta-2 microglobulin) |
| ldh | string | Yes | LDH: normal, high |
| cytogenetics | string | Yes | High-risk: del(17p), t(4;14), t(14;16) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| ≥ 3 | R-ISS III | 5-yr OS ~40% |
| ≥ 2 | R-ISS II | 5-yr OS ~62% |
| ≥ 1 | R-ISS I | 5-yr OS ~82% |
Evidence-Based References (EBM)
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma. J Clin Oncol. 2015;33(26):2863-2869.